BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Step 1 Inclusion Criteria:

* Histologically confirmed newly diagnosed nonsquamous non-small cell lung cancer (NSCLC), including the following subtypes:

  * Adenocarcinoma
  * Large cell undifferentiated
  * Bronchoalveolar cell
  * non-small cell carcinoma, not otherwise specified
* Unresectable stage IIIA or stage IIIB disease

  * Patients with stage IIIA disease with mediastinal lymph node enlargement between 1 cm and 2.0 cm on computerized tomography (CT) scan must have these nodes biopsied (pathologic confirmation) to rule out resectability
  * Metastases to contralateral mediastinal or supraclavicular nodes allowed
* Measurable or non-measurable disease, as defined by Response Evaluation Criteria in Solid Tumours (RECIST) criteria
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* White blood cell (WBC) ≥ 4,000/mm³ OR Absolute neutrophil count (ANC) ≥ 2,000/mm³
* Platelet count ≥ 140,000/mm³
* Hemoglobin ≥ 9.0 g/dL
* Total bilirubin ≤ 1.5 mg/dL
* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT)+ ≤ 2.5 times upper limit of normal
* Serum creatinine ≤ 1.5 mg/mL OR creatinine clearance ≥ 45 mL/min
* Urine protein:creatinine ratio \< 1.0 by urine dipstick OR \< 1 g of protein by 24-hour urine collection
* INR ≤ 1.5 OR ≤ 3.0 if patient is on therapeutic anticoagulation
* PTT normal
* Fertile patients must use effective contraception before, during, and for ≥ 6 months after completion of bevacizumab

Step 1 Exclusion Criteria:

* Significant pleural effusion
* CNS metastases by head CT scan or MRI within the past 4 weeks
* Pregnant or breast-feeding
* Prior chemotherapy or monoclonal antibodies for other cancers within 5 years prior to registration
* Prior chemotherapy for lung cancer
* Prior chest radiotherapy
* Ongoing (lasting \> 14 days) or active infection or ongoing (lasting \> 14 days) fever within the past 6 months
* Gross hemoptysis ≥ grade 2 (defined as ≥ ½ teaspoon of bright red blood per episode) within the past 3 months
* Bleeding ≥ grade 2 or any bleeding requiring intervention
* Clinically significant cardiovascular disease
* Myocardial infarction within the past 6 months
* New York Heart Association class III-IV congestive heart failure
* Unstable angina pectoris
* Serious cardiac arrhythmia requiring medication within the past 4 weeks
* History of hypertensive crisis or hypertensive encephalopathy
* Stroke or transient ischemic attack within the past 6 months
* Peripheral vascular disease ≥ grade 2 within the past 6 months
* Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
* Psychiatric illness or social situation that would limit compliance with study requirements
* History of uncontrolled hypertension (i.e., blood pressure ≥ 150/100 mm Hg) while on stable regimen of antihypertensive therapy
* Significant traumatic injury or serious non-healing wound, ulcer, or bone fracture within the past 4 weeks
* Concurrent major surgical procedure
* Having anticipated major surgical procedure(s) during the course of the study
* Concurrent daily aspirin (\> 325 mg/day) or nonsteroidal anti-inflammatory agents (NSAIDs) known to inhibit platelet function
* Recognized immunodeficiency disease, including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital immunodeficiencies
* Pre-existing medical condition requiring chronic steroids or immunosuppressive therapy
* Autoimmune disease
* Known hepatitis B or C
* Immunotherapy (e.g., interferon, interleukin, sargramostim \[GM-CSF\], or filgrastim \[G-CSF\]) within 28 days prior to registration
* Prior splenectomy
* Hypersensitivity to any component of bevacizumab
* Prior core biopsy or any other minor surgical procedure, excluding the placement of a vascular access device, within 7 days prior to registration

Step 2 Inclusion Criteria:

* Serum creatinine ≤ 1.5 mg/ml or calculated creatinine clearance ≥ 45 ml/min
* Urine dipstick must be ≤ 0-1+. If urine dipstick results \> 1+, 24 hour urine for protein must be obtained. Patients must have \< 1g protein/24 hours to participate in the study
* Patient must be registered to step 2 within 28 days of completion of consolidation chemotherapy
* Patient must have met all eligibility requirements for Step 1
* Platelets ≥ 100,000/mm3

Step 2 Exclusion Criteria:

* Progressive disease or unevaluable disease per RECIST criteria upon post- consolidation chemotherapy evaluation
* Autoimmune disease